Clinical Trial Detail

NCT ID NCT03076164
Title A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung adenocarcinoma

Therapies

Erlotinib + Trametinib

Age Groups: senior adult

Additional content available in CKB BOOST